|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2:A project of the Kyushu University Liver Disease Study Group显示文摘瞄准:决定一座干扰素高山的功效哈并且为感染遗传型 2 的丙肝病毒(HCV ) 的日本病人的 ribavirin 联合治疗,多中心研究回顾地被分析。方法:总共,有 HCV 遗传型 2 的 173 个病人每天一个星期和 ribavirin 的 600-800 mg 为 24 wk 三次皮下地收到 interferon-alpha。结果:总的来说持续的 virological 反应(SVR ) ,在浆液的定义同样无法发现的 HCV RNA,在治疗的结束以后的 24 wk,在 84.4% 显著地高,(146/173 ) 由 intention-to-treat 分析。在 SVR 的有效差量有或没有 ribavirin (46.9% 对 92.9%) 的中止在病人之间被发现,但是没有差别有或没有 ribavirin 的剂量减小在那些之间被发现。在 SVR 的有效差量也与 16 或更与不到 16 wk 和病人在病人之间被发现 ribavirin 治疗(34.8% 对 92.0%) 的星期。结论:24-wk 干扰素和 ribavirin 治疗为有 HCV 遗传型 2 的日本病人是高度有效的。SVR 的重要预言者是 ribavirin 治疗的继续多达 16 个星期。 | Norihiro Furusyo Masaki Katoh Yuichi Tanabe Eiji Kajiwara Toshihiro Maruyama Junya Shimono Hironori Sakai Makoto Nakamuta Hideyuki Nomura Akihide Masumoto Shinji Shimoda Kazuhiro Takahashi Koichi Azuma Jun Hayashi Kyushu University Liver Disease Study Group | 2006 | World Journal of Gastroenterology2006，12，5： | 8 |
| 2 | Hepatocyte Growth Factor Reduces Cardiac Fibrosis by Inhibiting Endothelial - Mesenchy- mal Transition 显示文摘 | Keita Okayama Junya Azuma Norio Dosaka | 2012 | Hypertension2012，59，5： | 1 |
| 3 | Telmisartan Exerts Renoprotective Actions via Peroxisome Proliferator-Activated Receptor-γ/Hepatocyte Growth Factor Pathway Independent of Angiotensin II Type 1 Receptor Blockade显示文摘 | Hiroshi Kusunoki Yoshiaki Taniyama Junya Azuma Kazuma Iekushi Fumihiro Sanada Rei Otsu Masaaki Iwabayashi Keita Okayama Hiromi Rakugi Ryuichi Morishita | 2012 | Hypertension2012，，2： | 1 |
| 4 | Hepatocyte Growth Factor Reduces Cardiac Fibrosis by Inhibiting Endothelial-Mesenchymal Transition显示文摘 | Keita Okayama Junya Azuma Norio Dosaka Kazuma Iekushi Fumihiro Sanada Hiroshi Kusunoki Masaaki Iwabayashi Hiromi Rakugi Yoshiaki Taniyama Ryuichi Morishita | 2012 | Hypertension2012，，5： | 1 |
| 5 | Hepatocyte Growth Factor Attenuates Transforming Growth Factor-β-Angiotensin II Crosstalk Through Inhibition of the PTEN/Akt Pathway显示文摘 | Kazuma Iekushi Yoshiaki Taniyama Hiroshi Kusunoki Junya Azuma Fumihiro Sanada Keita Okayama Nobutaka Koibuchi Masaaki Iwabayashi Hiromi Rakugi Ryuichi Morishita | 2011 | Hypertension2011，，2： | 1 |
| 6 | Hepatocyte growth factor attenuates renal fibrosis through TGF-β1 suppression by apoptosis of myofibroblasts显示文摘 | Kazuma Iekushi Yoshiaki Taniyama Junya Azuma Fumihiro Sanada Hiroshi Kusunoki Toyohiko Yokoi Nobutaka Koibuchi Keita Okayama Hiromi Rakugi Ryuichi Morishita | 2010 | Journal of Hypertension2010，，12： | 1 |
| 7 | Negative Action of Hepatocyte Growth Factor/c-Met System on Angiotensin II Signaling via Ligand-Dependent Epithelial Growth Factor Receptor Degradation Mechanism in Vascular Smooth Muscle Cells显示文摘 | Fumihiro Sanada Yoshiaki Taniyama Kazuma Iekushi Junya Azuma Keita Okayama Hiroshi Kusunoki Nobutaka Koibuchi Takefumi Doi Yoshifusa Aizawa Ryuichi Morishita | 2009 | Circulation Research2009，，7： | 1 |
| 8 | Hepatocyte Growth Factor, but not Vascular Endothelial Growth Factor, Attenuates Angiotensin II–Induced Endothelial Progenitor Cell Senescence显示文摘 | Fumihiro Sanada Yoshiaki Taniyama Junya Azuma Kazuma Iekushi Norio Dosaka Toyohiko Yokoi Nobutaka Koibuchi Hiroshi Kusunoki Yoshifusa Aizawa Ryuichi Morishita | 2009 | Hypertension2009，，1： | 1 |
| 9 | Relationship between body surface area and ALT normalization after long-term lamivudine treatment显示文摘AIM: To further evaluate the relationship between BSA and the effects of lamivudine in a greater number of cases and over a longer period of observation than in our previous evaluation.METHODS: We evaluated 249 patients with chronic hepatitis B. The effects of treatment for one year (n = 249),two years (n = 147), and three years (n = 72) were evaluated from the levels of serum ALT and HBV-DNA,as biological and virological effects (undetectable levels by PCR), respectively. Moreover, several variables that could influence the response to treatment, including ALT,albumin, bilirubin, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed.RESULTS: For 1-year treatment, multivariate analysis revealed that BSA (P=0.0002) was the only factor for the biological effect, and that ALT (P = 0.0017), HBVDNA (P = 0.0004), and HBeAg (P = 0.0021) were independent factors for the virological effect. For 2-year treatment, multivariate analysis again showed that BSA(P = 0.0147) was the only factor for the biological effect,and that ALT (P = 0.0192) and HBeAg (P = 0.0428) were independent factors for the virological effect. For 3-year treatment, multivariate analysis, however, could not reveal BSA (P = 0.0730) as a factor for the normalization of ALT levels.CONCLUSION: BSA is a significant predictor for the normalizing the effect of lamivudine therapy on ALT for an initial 2-year period, suggesting that lamivudine dosage should be based on the individual BSA. | Makoto Nakamuta Shusuke Morizono Yuichi Tanabe Eiji Kajiwara Junya Shimono Akihide Masumoto Toshihiro Maruyama Norihiro Furusyo Hideyuki Nomura Hironori Sakai Kazuhiro Takahashi Koichi Azuma Shinji Shimoda Kazuhiro Kotoh Munechika Enjoji Jun Hayashi Kyushu University liver Disease Study Group | 2005 | World Journal of Gastroenterology2005，11，44： | 1 |
| 10 | Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C显示文摘AIM:To analyze the efficacy and safety of a combination therapy of pegylated interferon(PEG-IFN) α-2b plus ribavirin(RBV) in older Japanese patients(65 years or older) infected with hepatitis C virus(HCV).METHODS:This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk.RESULTS:At 24 wk after the end of combination therapy,the overall sustained virological response(SVR) for genotypes 1 and 2 were 40.7% and 79.6%,respectively.The SVR rate decreased signif icantly with age in each genotype,and was markedly reduced in genotype 1(P<0.001).Moreover,the SVR was significantly higher in patients with genotype 1 who were less than 65 years(47.3% of 685) than in those 65 years or older(22.9% of 253)(P<0.001) and was higher in patients with genotype 2 who were less than 65 years(82.9% of 252) than in those 65 years or older(65.6% of 61)(P=0.004).When patients received a dosage at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target dosage of RBV,the SVR rate significantly increased to 66.5% in patients less than 65 years and to 45.2% in those 65 years or older(P<0.001).Adverse effects resulted in treatment discontinuation more often in patients with genotype 1(14.4%) than in patients with genotype 2(7.3%),especially by patients 65 years or older(24.1%).CONCLUSION:PEG-IFN α-2b plus RBV treatment was effective in chronic hepatitis C patients 65 years or older who completed treatment with at least the minimum acceptable treatment dosage. | Mosaburo Kainuma Norihiro Furusyo Eiji Kajiwara Kazuhiro Takahashi Hideyuki Nomura Yuichi Tanabe Takeaki Satoh Toshihiro Maruyama Makoto Nakamuta Kazuhiro Kotoh Koichi Azuma Junya Shimono Shinji Shimoda Jun Hayashi | 2010 | World Journal of Gastroenterology2010，16，35： | 1 |
| 11 | Long-term lamivudine treatment for chronic,hepatitis B in Japanese patients:A project of Kyushu University Liver Disease Study显示文摘瞄准:与长期的肝炎 B 决定很多日本病人的长期的 lamivudine 治疗的功效。方法:在这回顾,多中心试用,有长期的肝炎 B 的 318 个日本病人每天为多达 36 收到了 lamivudine 的 100 mg (中部 21 ) 瞬间。Virological 反应是到浆液 HBV DNA 水平的衰落不到 3.7 木头 copies/mL。当浆液 HBV DNA 的再现在 treatment.RESULTS 期间铺平最小到超过 10 褶层, Virological 突破被定义:Lamivudine 在 6 瞬间在 318 个病人中的 86.8% 个生产了 virological 反应,在在 12 瞬间的 252 个病人中的 80.2% 个,在在 24 瞬间的 133 个病人中的 69.2% 个,并且在在 36 瞬间的 28 个病人中的 53.6% 个。向前逐步的逻辑回归分析证明 HBV DNA 铺平不到 6.8 木头 copies/mL ( P<0.0001 ), HBeAg 否定性( P<0.0001 ), 100 x 10 的一个血小板计数( 9 )在基线的 /L 或更多( P=0.0162 ),并且超过 3.2 木头 copies/mL 的 HBV DNA 水平的衰落在治疗( P=0.0003 )的开始以后在 3 瞬间作为与基线相比铺平显著地与 virological 反应被联系。在有 virological 回答的病人之中, virological 突破在在 1 瞬间 virologically 反应了的 19 个病人中的5.3%个被看见,在在 3 瞬间的 203 个病人中的20.7%个,在在 6 瞬间的 51 个病人中的27.5%个,在在 9 瞬间的 12 个病人中的33.3%个,并且在在 >=5 瞬间的 3 个病人的100%。virological 突破与推迟的 virological response.CONCLUSION 在病人更经常显著地被发现:Lamivudine 治疗能在大多数测试日本病人压制浆液 HBV DNA。没有 HBeAg,长期的功效可能在基线在病人被看见,当肝硬化不在时,并且在有在 HBV 的衰落的病人, DNA 此后不久铺平治疗的开始。 | Norihiro Furusyo Hiroaki Takeoka Kazuhiro Toyoda Masayuki Murata Yuichi Tanabe Eiji Kajiwara Junya Shimono Akihide Masumoto Toshihiro Maruyama Hideyuki Nomura Makoto Nakamuta Kazuhiro Takahashi Shinji Shimoda Koichi Azuma Hironori Sakai Jun Hayashi | 2006 | World Journal of Gastroenterology2006，12，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员